How would you approach adjuvant treatment for an ampullary adenocarcinoma with mixed intestinal and pancreatobiliary histology?
For a mixed-phenotype ampullary adenocarcinoma, adjuvant management requires multidisciplinary evaluation to identify the predominant lineage between the intestinal and pancreatobiliary histology, as treatment protocols follow the predominant histological lineage noted on expert pathology review. However, if both histology components are equally dominant, management is skewed to the pancreatobiliary phenotype algorithm. Because pancreatobiliary ampullary tumours exhibit significantly higher rates of lymph node metastasis, earlier recurrence, and worse overall survival compared to intestinal subtypes; treating aggressively with a pancreatobiliary-directed regimen addresses the more virulent clone. In addtion to the histology subtype, adjuvant chemotherapy decision-making puts into consideration other pathological characteristics including lymph node positivity, depth of invasion, lymphovascular invasion, perineural invasion, and high histological grade.
Discuss the role of pathology review, additional immunohistochemistry, and the factors that should guide treatment selection.
Re-evaluation by a specialized gastrointestinal pathologist ensures accurate histologic categorization and confirms negative surgical margins, which are key prognostic factors and important for decision on adjuvant chemotherapy. Immunohistochemistry (IHC) resolves mixed ambiguity by assigning the predominant immunophenotype. The Pancreatobiliary Subtype is usually positive for CK7, MUC1, and MUC5AC; and negative for CK20 and CDX2. While the Intestinal Subtype is typically positive for CDX2, CK20, and MUC2; negative for CK7 and MUC1. The Pathologic stage, immunohistochemistry type and Performance status are important key considerations in treatment decision making
If the tumour is confirmed to be of the pancreatobiliary subtype, which adjuvant chemotherapy regimen would you recommend? Justify your recommendation using current evidence and clinical practice guidelines.
:
For patients with good performance status who are chemotherapy naïve, Gemcitabine and Capecitabine would be my preference. This decision is supported by the BILCAP trial and ESPAC-3/ESPAC-4 trial sub-analyses, showing improved overall survival in resected biliary tract and periampullary cancers compared to gemcitabine monotherapy.
Also, modified FOLFIRINOX regimen can be used as an alternate regimen for patients unable to tolerate Gemcitabine and Capecitabine combination. This is supported by Extrapolated from resected pancreatic ductal adenocarcinoma (PRODIGE 24/CACC 11 trial) for exceptionally fit patients (ECOG 0–1) with high-risk features (e.g., node-positive disease).
For patients with poor performance status, Gemcitabine Monotherapy or Capecitabine Monotherapy is used.
The patient asks whether she could receive targeted oral therapy instead of conventional intravenous chemotherapy to reduce hospital visits. Which predictive molecular biomarkers should be tested on the surgical specimen, and how would the results influence the use of targeted therapies or immunotherapy?
Oral targeted therapy cannot completely substitute for standard cytotoxic chemotherapy without actionable biomarker findings. The surgical specimen should be submitted for Comprehensive Genomic Profiling (CGP) and IHC to test for the following predictive biomarkers:
MSI / dMMR Status (Mismatch Repair Deficiency / Microsatellite Instability). If MSI-High/dMMR is detected, the patient is eligible for Pembrolizumab (PD-1 immune checkpoint inhibitor).
HER2 / ERBB2 Status (IHC / FISH or Gene Amplification). Overexpression/amplification enables targeted dual-HER2 blockade (e.g., Trastuzumab + Pertuzumab) or antibody-drug conjugates (e.g., Trastuzumab Deruxtecan) in subsequent lines.
NTRK1/2/3 Gene Fusions. Fusions qualify the patient for targeted oral TRK inhibitors (Larotrectinib or Entrectinib).
KRAS Mutation Status. KRAS G12C mutation allows consideration of targeted oral KRAS G12C inhibitors (e.g., Sotorasib or Adagrasib) upon progression.
Germline/Somatic BRCA1/2 and PALB2 Mutations. Alterations in homologous recombination repair genes support platinum-based chemotherapy sensitivity and potential maintenance therapy with oral PARP inhibitors (e.g., Olaparib).
Targeted oral therapies and immunotherapies are restricted to tumors harbouring these specific genomic alterations and are primarily validated in advanced, metastatic, or recurrent settings. In the curative adjuvant setting (post-R0 resection), standard intravenous systemic chemotherapy remains the established standard of care
Reference:
Gutman J, Friedlaender A, Mechahougui H. Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. International Journal of Molecular Science, 2026; 27:1597- 1609